Skip to main content
Immunovia logo

Immunovia — Investor Relations & Filings

Ticker · IMMNOV ISIN · SE0006091997 LEI · 549300KHWL6KK1XGUO81 ST Human health and social work activities
Open in API
Filings indexed 378 across all filing types
Latest filing 2024-08-12 Capital/Financing Update
Country SE Sweden
Listing ST IMMNOV

About Immunovia

https://immunovia.com/

Immunovia is a diagnostics company focused on revolutionizing the early detection of pancreatic cancer. Its primary product is the PancreaSure test, a simple blood test designed to detect pancreatic cancer at Stage 1 and 2 with high accuracy. The test is intended for annual surveillance of individuals at elevated risk due to family history or genetic mutations. PancreaSure functions by detecting proteins and other biomarkers indicative of pancreatic cancer growth. The company's mission is to improve survival rates for this highly lethal cancer by enabling diagnosis at its earliest, most treatable stages, offering a convenient alternative to invasive imaging procedures.

Recent filings

Filing Released Lang Actions
Immunovia publishes prospectus in connection with forthcoming rights issue
Capital/Financing Update Classification · 98% confidence The document is explicitly titled as a "PRESS RELEASE" announcing that "Immunovia publishes prospectus in connection with forthcoming rights issue." It details the terms of a rights issue (subscription price, unit structure, timeline, intended use of proceeds) and repeatedly refers to the official document as the "Prospectus" which has been approved by the Swedish Financial Supervisory Authority. A rights issue is a form of capital raising/financing activity. Since the document is an announcement detailing the terms of a financing event (Rights Issue) and the associated official document (Prospectus), it directly falls under the definition of Capital/Financing Update (CAP). It is not the full Annual Report (10-K), an Earnings Release (ER), or a simple Report Publication Announcement (RPA) because it contains substantial details about the financing terms, not just a notification that a report is available.
2024-08-12 English
Immunovia offentliggör prospekt i samband med företrädesemission
Capital/Financing Update Classification · 98% confidence The document is a press release ("PRESSMEDDELANDE") from Immunovia AB dated August 12, 2024, announcing the publication of a prospectus ("Prospektet") related to a rights issue ("företrädesemission"). It details the terms of the offering (units, shares, warrants, subscription price, timeline) and explicitly states that the prospectus has been approved by the Swedish Financial Supervisory Authority (Finansinspektionen) and is available on the company's website. The text itself is an announcement about a financing/capital event (rights issue) and the associated regulatory document (prospectus). Since the document is announcing the availability of a prospectus for a capital raise (rights issue involving new shares and warrants), it falls under the category for Capital/Financing Updates (CAP). Although a prospectus is a specific document, the primary action described here is the financing activity itself, which is best captured by CAP. If the document were the full prospectus, it might be classified differently, but as a press release announcing the offering and the prospectus, CAP is the most appropriate fit among the provided options, as it details fundraising activities.
2024-08-12 Swedish
Declaration of Voting Results & Voting Rights Announcements 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document details a change in shareholding percentage for a specific holder (Avanza Bank Holding AB for Försäkringsaktiebolaget Avanza Pension) in the issuer (Immunovia AB). It explicitly mentions 'Reason for major shareholding notification Buy' and shows the 'Before' and 'After the transaction' holdings, including the resulting percentage (10.18202%). This structure perfectly matches the definition of a Major Shareholding Notification, which is categorized as 'MRQ' in the provided schema.
2024-08-07 English
Immunovia offentliggör slutliga villkor i företrädesemission
Capital/Financing Update Classification · 98% confidence The document is a press release from Immunovia AB, dated August 6, 2024, announcing the final terms of a rights issue ('Företrädesemission'). The text details the structure of the offering (units consisting of shares and warrants/options - TO 2 and TO 3), the subscription price (1.02 SEK per unit), the expected capital raised (approx. 69.3 MSEK initially), the subscription period (August 16 - August 30, 2024), and the dilution effects. This content directly relates to the company's fundraising and capital structure changes. Therefore, the most appropriate classification is 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it describes a specific corporate financing action.
2024-08-06 Swedish
Immunovia announces final terms of rights issue
Capital/Financing Update Classification · 99% confidence The document is a press release dated August 6, 2024, announcing the 'final terms of rights issue' for Immunovia AB. It details the structure of the rights issue (units, shares, warrants), subscription price, expected proceeds, subscription period (August 16 - August 30, 2024), and the impact on share capital and dilution. This content directly relates to a company fundraising or capital structure change event. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). Although it mentions the Annual General Meeting approved the issue, the core subject is the financing terms, not AGM materials or voting results.
2024-08-06 English
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is titled 'DELÅRSRAPPORT JANUARI-JUNI 2024' (Interim Report January-June 2024). It contains comprehensive financial statements, including income statements, balance sheets, cash flow statements, and management commentary for the interim period. It is not a short announcement, but a full report, thus fitting the definition of an Interim/Quarterly Report (IR). H1 2024
2024-08-05 Swedish

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.